| 7/13/2010 | CVLM | OSI sets expiration on purchase offer for 2% convertibles at July 30; holders convert all 3% notes
|
| 6/18/2010 | CV | OSI 2% notes now convertible through July 19 on another major change
|
| 6/9/2010 | CV | OSI 2% notes are convertible through July 8 due to fundamental change
|
| 6/4/2010 | CV | OSI 2% notes remain convertible through July due to fundamental change
|
| 5/18/2010 | CV | Market Commentary: Convertibles quiet amid market uncertainty; Massey Energy steady to higher on lower shares
|
| 5/17/2010 | CV | Market Commentary: OSI takeout protection falls short on 3% convertibles; GLG jumps on takeout; Sybase steady
|
| 5/6/2010 | CVLM | OSI holders convert nearly all 3.25% convertibles ahead of redemption
|
| 4/1/2010 | CV | OSI Pharmaceuticals' 2% senior notes now convertible through June 30
|
| 3/22/2010 | CV | OSI Pharmaceuticals calls its remaining 3.25% convertibles due 2023
|
| 3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
| 3/1/2010 | CV | Market Commentary: Millipore a little weaker dollar neutral, but OSI Pharma expands; Amylin, Isis also in trade
|
| 12/22/2009 | CV | OSI buys back $79.5 million of convertibles for $75 million to date
|
| 7/23/2009 | CV | Market Commentary: Earnings help convertibles extend strength; Ford gains on profit; OSI, Human Genome higher
|
| 4/22/2009 | CV | Market Commentary: Watson, OSI add on buyout rumors; Alexandria up; Ford jumps, GM mixed; Old Republic to price
|
| 4/3/2009 | CV | OSI Pharmaceuticals 2% notes are convertible through June 30
|
| 12/4/2008 | CV | Market Commentary: Prudential longer paper gains; ImClone weaker; Advanced Micro mostly quiet on lowered outlook
|
| 10/1/2008 | CV | OSI Pharmaceuticals says 2% notes will remain convertible in fourth quarter
|
| 7/3/2008 | CV | OSI's 2% notes due 2025 are convertible
|
| 5/8/2008 | CV | OSI Pharmaceuticals buys back $37.9 million 3.25% convertibles
|
| 4/4/2008 | CV | OSI holders may convert 2% notes through second quarter
|
| 1/15/2008 | CV | OSI Pharmaceuticals greenshoe exercised in full, lifts 3% convertibles due 2038 to $200 million
|
| 1/8/2008 | CV | OSI Pharmaceuticals notes will be convertible through first quarter
|
| 1/4/2008 | CV | New Issue: OSI Pharmaceuticals prices upsized $175 million 3% convertible notes, up 65%
|
| 1/4/2008 | CV | Market Commentary: Sallie slammed, drags down financials; Intel panned; drags down chips; OSI opens strong
|
| 1/3/2008 | CV | Market Commentary: OSI deal looks cheap; Superior up on new contract; Ford slips; Intel, AMD continue dive; market slows
|
| 1/3/2008 | CV | Market Commentary: OSI deal looks cheap; Superior up on new contract; Ford slips; Intel, AMD continue dive; market slows
|
| 1/2/2008 | CV | OSI Pharmaceuticals launches $150 million 30-year convertible notes; talked at 3%-3.5%, up 57.5%-62.5%
|
| 1/2/2008 | CV | Market Commentary: Investors get good look at Sallie Mae; Intel drags down chips; near record gold drives Newmont surge
|
| 1/2/2008 | CV | OSI Pharmaceuticals plans to repurchase 3.25% convertibles
|
| 7/10/2007 | CV | OSI Pharmaceuticals 2% notes to remain convertible
|
| 1/9/2007 | CV | OSI Pharmaceuticals 2% notes to remain convertible through first quarter
|
| 10/20/2006 | BTCV | OSI Pharmaceuticals says holders may convert 2% convertibles through Dec. 29
|
| 2/6/2006 | CV | Market Commentary: Huntsman converts fall as sale dropped; Transocean rises on new contracts; JetBlue slides on worries
|
| 12/30/2005 | BTCV | OSI Pharmaceuticals underwriter exercises greenshoe, raising convertibles to $115 million
|
| 12/16/2005 | CV | Market Commentary: OSI Pharmaceuticals new issue rises, but ON Semiconductor slips; Carnival lower on higher dividend fears
|
| 12/16/2005 | BTCV | New Issue: OSI Pharmaceuticals $100 million 20-year convertibles yield 2%, up 25%
|
| 12/15/2005 | CV | Market Commentary: ON Semi, OSI Pharma at bat; Entergy goes to 50.5 bid; Intel steady; Abgenix issues climb
|
| 12/15/2005 | BTCV | OSI Pharma prices $100 million 20-year convertibles talked to yield 2%, up 25%
|
| 12/14/2005 | CV | Market Commentary: Intel, Ceradyne trade higher; United Dominion re-offered; Entergy up in gray; OSI launches $100 million
|
| 12/14/2005 | BTCV | OSI Pharma $100 million 20-year convertibles talked to yield 1.75%-2.25%, up 20%-25%
|
| 8/26/2005 | CV | Market Commentary: DOV Pharmaceutical convertibles tumble; Atherogenics adds; Agilent active on call news
|
| 8/22/2005 | CV | Market Commentary: Convertibles of Northwest Airlines firm; OSI Pharma drops on acquisition; CP Ships lifts on offer
|
| 7/19/2004 | CV | OSI holders convert all $160 million of 4% notes to 3.2 million shares
|
| 6/18/2004 | CV | Market Commentary: OSI Pharma 4% convertible falls 6 points on call; Delta soars on bets pilots cave, no bankruptcy
|
| 6/18/2004 | CV | OSI Pharmaceuticals calls $160 million of 4% convertibles
|
| 6/7/2004 | CV | Market Commentary: Mandalay event sparks furor on concern about no cash takeover protection; 20-30 names suffer
|
| 5/12/2004 | CV | Market Commentary: CV Therapeutics bid at 100.375 in gray market; Pixelworks still; OSI Pharma, ImClone up sharply
|
| 4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
| 4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
| 3/3/2004 | CV | Market Commentary: Disney little changed on concerns besides Eisner; PSS soars to 106; Toys up on hoped-for store sales
|
| 11/20/2003 | CV | Lehman prefers OSI Pharmaceuticals 3.25% convertibles over 4% converts on cheapness
|
| 9/4/2003 | CV | Market Commentary: Issuance seen slowing, with more classic small cap issuers; Gap plunges; techs mostly higher
|
| 9/3/2003 | CV | New Issue: OSI Pharmaceuticals $135 million convertibles yield 3.25%, up 32.5%
|
| 9/3/2003 | CV | Market Commentary: Rite Aid drops 3 points as Merrill pans stock; Openwave bid up in gray; OSI Pharmaceuticals dips
|
| 9/2/2003 | CV | OSI Pharmaceuticals launches $135 million convertible
|
| 9/2/2003 | CV | Market Commentary: Traders see activity pick up, largely in anticipation of new deals waiting in the wings
|
| 1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
| 9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
| 8/29/2002 | CV | OSI Pharmaceuticals buys back $40 million convertibles on "over-reaction"
|
| 8/22/2002 | CV | Wachovia analyst: Not all is lost for OSI Pharmaceuticals' drug prospect
|
| 8/20/2002 | CV | Market Commentary: New deals stimulate players; retailers find bargain hunters
|
| 8/19/2002 | CV | Market Commentary: OSI, ImClone wounded; retailers build on strong surge at Lowe's
|
| 7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
| 5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
| 5/14/2002 | CV | Market Commentary: Broadbased gains as better retail sales confirm recovery signs
|
| 1/30/2002 | CV | Market Commentary: Convertibles snap back somewhat but witch-hunt continues
|
| 1/29/2002 | CV | Market Commentary: Convertibles spiral sharply lower on witch-hunt for accounting flags
|
| 1/29/2002 | CV | New Issue: OSI Pharmaceuticals upsized $200 million convertibles yield 4.0%, up 23.3%
|
| 1/28/2002 | CV | Market Commentary: Convertibles market preps for new deals, telecoms sink on Global Crossing bankruptcy
|
| 1/25/2002 | CV | Market Commentary: Convertibles flat as braces for busy week ahead
|
| 1/24/2002 | CV | OSI Pharmaceuticals $150 million convertibles talked 4.0-4.5% yield, up 17.5-22.5%
|
| 1/24/2002 | CV | Market Commentary: Awaiting Ford terms, convertibles flat as market watched Greenspan, Enron hearings
|
